Backgrounds: By a new concept called "phase diagram", we compare two commonly used genotype-
Introduction
Comparing allele and genotype frequencies of a single marker between the patients and normal people (Sasieni, 1997; Lewis, 2002; Li, 2008) remains the core of a case-control genetic association analysis, prior to a haplotype analysis and bioinformatic analysis to determine the spatial extent and gene context of the signal. The success of a genetic association study crucially depends on study design (Amos, 2007) , but the choice of test is also somewhat important. If we focus on genotype-based tests, i.e., each observed genotype is a sample instead of two allele samples (Sasieni, 1997) , there are many possible types of tests to choose from.
For example, the Pearson's goodness-of-fit test on the 2-by-3 genotype count table, CochranArmitage trend (CAT) tests with a single parameter value x which determines the relative risk of heterozygote with respect to the two homozygotes (Sasieni, 1997; Devlin and Roeder, 1999; Slager and Schaid, 2001) , tests that are maximized over two or more tests (Yamada et al., 2001; Freidlin et al., 2002; Tokuhiro et al., 2003; Zheng et al., 2006a) , and those that stepwisely use a few tests sequentially (Zheng et al., 2008) . This quote from (Balding, 2006) might capture the feeling about the current state: "there is no generally accepted answer to the question of which single-(marker) test to use" in genetic case-control association analysis. The widespread use of whole-genome association in the study of complex diseases nowadays (Wellcome Trust Case Control Consortium, 2007) adds an urgency in having a better understanding of this issue.
If one statistical test is always more powerful than another test, the first test should of course be used all the time. However, each test may have its own strength and weakness depending on the true underlying model. For example, Cochran-Armitage trend as a family of tests is to test the equality of genotype frequencies in the case and the control group, but as a test at a parameter x is to test the null hypothesis P case (AA)+xP case (Aa) = P control (AA)+xP control (Aa) (AA is the risk genotype, and P (AA) is its frequency; similarly for heterozygous genotype Aa).
The CAT test at x = 0 is most powerful for detecting recessive disease genes, whereas it is more powerful at x = 0.5 when Hardy-Weinberg equilibrium (HWE) holds for case and control groups. For a pair of tests, in the space of all possible disease models, the first test can be more powerful in some regions whereas the second test is more powerful in other regions. This simple picture is reminiscent of the phase diagram in physics (e.g., Gibbs, 1873; Lifshitz and Landau, 1980) where a phase can be solid, liquid or gas depending on the temperature, pressure, or other relevant quantities. In our case-control genetic test example, the aim of phase diagram is to graphically depict regions where specific test is more powerful than others. Note that one should not confuse the usage of "phase" here with the meaning often used in genetics, i.e., of the "parental origin" of an allele in a genotype (e.g. Scheet and Stephens, 2006) .
Although the principle of our phase diagram can be established as discussed above, there are several practical considerations. First, a disease model is specified by many parameters, and one may wonder whether the phase structure can be seen in a two-dimensional space.
Second, if the two phases are highly intermingled in one parameterization, we may ask if other parameterization schemes are better suited for separating the two phases. Third, besides the definition of phases which are based on statistical power, we can also define phases that are based on p-value, and the question is whether the two ways of defining phase diagrams are similar. This paper uses a specific pair of tests to address these questions and to show the utility of this approach.
The motivation of our study is to discuss the issue of in what circumstances, one should use a particular test instead of others. We first study the parameterization of phase diagram, then construct two phase diagrams, one power-based and another p-value-based, for a pair of commonly used tests. The phase boundary in both versions of phase diagram will be determined. And we examine several whole-genome association datasets using the phase diagram.
Several other applications of the phase diagram are also discussed, including comparison of two random simulations of disease models, and graphical display of case-control data of many SNPs.
Methods
Case-control difference of allele frequency and Hardy-Weinberg disequilibrium (HWD) coefficient given a disease model A single-locus biallelic disease model can be specified by four parameters: three penetrances f i =Prob(disease|G i ) (i = 0, 1, 2) where {G i } are the three genotypes aa, aA, AA, and the population A-allele frequency p. Alternatively, one can use the allele frequency p, two relative genotype risks λ i = f i /f 0 (i = 1, 2), and disease prevalence
to specify the disease model. Denote A-allele frequency in case and control group as p 1 and p 0 , and HWD coefficient (Weir, 1996) in case and control group as ǫ 1 and ǫ 0 ; all four (p 1 , p 0 , ǫ 1 , ǫ 0 )
can be derived from a given disease model, under the assumption that HWE holds true for the general population that contains both cases and controls (Wittke-Thompson et al., 2005) .
We use the difference of A-allele frequency (δ p ) and the difference of HWD coefficients (δ ǫ ) in case and control group as the parameters for our phase diagram:
When λ 1 > 1 and λ 2 > 1, A-allele is enriched in the case group, and δ p is always positive. On the other hand, if λ 1 < 1 and λ 2 < 1, A-allele is depleted in the case group and δ p is negative.
To be consistent, we call A the risk allele when δ p > 0. Whether A-allele is a minor allele (p < 0.5) or a major allele (p > 0.5) does not by itself affect the sign of δ p and δ ǫ .
Case-control difference of allele frequency and Hardy-Weinberg disequilibrium coefficient given a genotype count table 
For notation simplicity, the hat (ˆ) will be removed later on, and whether the model-based or data-based usage is applied should be clear from the context.
Note that switching the A and a allele, or equivalently, switching the first and the third column in Table 1 , changes the sign of δ p , whereas the sign of δ ǫ is unaffected. Eq.(2) also shows another advantage of using the difference of two HWD coefficients: if the disequilibrium is sensitive to typing errors, its effect is minimized when the differenceδ ǫ is used.
Cochran-Armitage trend test and MAX2 test
Cochran-Armitage trend (CAT) test at parameter x assigns a score of 0, x, and 1 for genotypes aa, aA, and AA, for log-risk relative to the baseline aa genotype (Sasieni, 1997; Devlin and Roeder, 1999; Slager and Schaid, 2001) . Sometimes, the name of Cochran-Armitage trend test is used to only refer to that at parameter x = 0.5 (Balding, 2006) , which we will call as CAT0.5. On the other hand, CAT at parameter settings of x = 0 and x = 1 is equivalent to assuming recessive and dominant models, which we will refer to as CAT0 and CAT1.
With the genotype count in Table 1 , the test statistic of CAT0.5, CAT0, and CAT1 can be derived (see, e.g., Sasieni, 1997). We re-parameterize these test statistics using a new set of parameters including δ p and δ ǫ :
where
.5 usually leads to very similar result to the allele-based test.
But since CAT0.5 is a genotype-based test, it does not have the problem of allele-based test for artificially doubling the sample size (Sasieni, 1997).
The MAX2 test is defined by the maximization of the CAT0 and CAT1 test statistics:
. Although MAX2 has been used in a few analyses (e.g., Yamada et al., 2001; Tokuhiro et al., 2003) , it did not have a formal name. The name of MAX2 used here is to distinguish it from the MAX3 test (max(CAT 0, CAT 1, CAT 0.5)) proposed in (Freidlin et al., 2002 
where P 0 is the null distribution, p X2 is the p-value for a χ 2 -distributed test statistic. In R code (http://www.r-project.org/), the command for calculating p-value for MAX2 is 1-pchisq(MAX2, df=1)^2.
For dataset generated by a known disease model, CAT test statistics follow chi-square distributions with non-central parameters. The non-central parameters for CAT0.5, CAT0
and CAT1 are given in Eq.(3), only that δ p , δ ǫ , and other parameters are determined by the disease model, not from the data. Alternatively, power can be determined empirically by simulation.
Simulation
For empirical power calculation, we sampled N r (=5000) replicates of genotypes for N case (=500) cases and N control (=500) controls, given a disease model. In Fig.2 , N m (=10000) disease models were generated randomly. The relative genotype risks λ 1 and λ 2 are randomly selected from a range (e.g., (0.5-2)), and the population A-allele frequency is randomly selected (e.g., from (0.1-0.9)). The type I error is set at 0.05 and we have determined the test statistic threshold for MAX2 either by permutation or by Dunn-Sidák formula. Due to the consistency between the two approaches, the type I error is controlled mostly by using the Dunn-Sidák formula in Eq.(4). The empirical power of CAT0.5 or MAX2 at the given type I error is determined by the proportion of replicates that exceeds the threshold.
For the phase diagram in Fig.4 under the null model (i.e., same allele and genotype frequency according to the HWE), N r (=2000) replicates of genotype were generated for N case (=500) cases and N control (=500) controls.
Results
Phase diagrams based on power given the disease model
In the δ ǫ -δ p space, known types of disease models such as dominant, recessive, additive, multiplicative, and over-dominant models fall in different regions of the plane, after requiring the risk allele A to have higher frequency in cases than in controls, as can be seen from Fig.1 .
For example, recessive models reside in the first quadrant, additive, dominant, over-dominant models are in the second quadrant, and the multiplicative models sit along the y-axis.
We pick CAT0.5 and MAX2 as the two tests to compare for the following reasons. First, allele-based test is still one of the most commonly used tests in case-control genetic analysis, and we would like to choose a similar genotype-based test. Second, we want to choose a test that is robust against disease model mis-specification. These two considerations lead to CAT0.5 and MAX2. is limited to a narrow angle around the y-axis. For regions far away from the x-axis, both tests lead to close to 100% power (the symbol "1" is used to mark the points when both power(CAT0.5) and power(MAX2) are larger than 0.99). The phase boundary in the first (and the third) quadrant can be roughly approximated by the line θ = tan −1 (δ p /δ ǫ ) = 73.125
• (13π/32). The phase boundary in the second (and the fourth) quadrant is not sharp with some degree of overlap between the two phases. However, the line θ = tan −1 (δ p /δ ǫ ) = 106.875
• (19π/32) seems to provide a reasonable boundary to phase 2 points.
The phase structure presented in Fig.2 is consistent with our current knowledge that allelebased test and CAT0.5 are most powerful for multiplicative models. In fact, it can be shown that non-central parameter in the χ 2 distribution for the allele-based test is strictly larger than that of either CAT0 or CAT1 (i.e., either one of two ways to combine heterozygote counts with the homozygote counts), if (1) ǫ 1 = ǫ 0 = 0 and (2) N 1 = N 0 (Suh and Li, 2007) . However, it was somewhat surprising that the two phases in Fig.2 To have a better understanding of the phase structure, in Fig.3 , we plot the power of CAT0.5
as a function of |δ p | as well as power of MAX2 as a function of radius δ 2 p + δ 2 ǫ . As expected, the power of CAT0.5 increases as the allele frequency difference is larger, because CAT0.5 is very close to the allele-based test which is designed to detect allele frequency differences. On the other hand, it was unexpected that the power of MAX2 increases with the radius, and the increase follows a similar way as power of CAT0.5 increases with |δ p |. If we draw the two plots in one, the two more or less overlap. In a crude approximation, suppose power(CAT0.5) vs.
|δ p | and power(MAX2) vs. δ 2 p + δ 2 ǫ follow the same functional form, then the power of MAX2 should be larger than that of CAT0.5 over the whole plane except the y-axis, because radius is always larger than the y value except for the y-axis. Although this is only an approximation, 
Phase diagrams based on p-values given the genotype data
Power analysis is always discussed in a theoretical context because it requires our knowing of the true disease model. In reality, the disease model is not supposed to be known. Towards a data-driven concept of phase diagram, we define the following phase diagram based on p-values.
As can be seen from Eq.(3), the relative magnitude of CAT0.5 and MAX2 test statistics depends on the estimated value of four parameters p 1 , p 0 , ǫ 1 , ǫ 0 , as the common factor N 1 N 0 /N is canceled out. If we assume that averaged quantities such as p and ǫ do not vary dramatically with different p 1 , p 0 , ǫ 1 , ǫ 0 values, then the relative magnitude of CAT0.5 and MAX2 test statistics are mainly determined by the parameters δ p and δ ǫ .
Because of the multiple testing in MAX2, even if a MAX2 test statistic is larger than that of CAT0.5, the MAX2 p-value may not be smaller than the p-value by CAT0.5. It should be noted that the assumption to apply Dunn-Sidák formula in Eq.(4), i.e., the independence between the two terms to be maximized, does not hold exactly. However, the correlation between CAT0 and CAT1 is actually small. It was shown in (Freidlin et al., 2002; Zheng et al., 2006a ) that the correlation between CAT0 and CAT1 test statistics under the null hypothesis
This correlation is at most 1/3 which is reached when p 1 = p 0 = 0.5. Simulation shows that Dunn-Sidák formula leads to an accurate estimation of p M AX2 , despite a weak violation of the assumption. This is in a contrast with MAX3, where the correlation between CAT0.5 and either CAT1 or CAT0 is too strong to apply the Dunn-Sidák formula (González et al., 2008; Li et al., 2008) . control HWD coefficients (ǫ 1 , ǫ 0 ) and their difference (δ ǫ ), the angle θ in the δ p − δ ǫ phase diagram with respect to either x or y axis, and CAT test statistics at x = 0.5, 0, 1.
There are several observations made from Table 2(B). As expected, the estimated HWD coefficient in case group ǫ 1 is usually larger in magnitude than that in control group ǫ 0 . However, the largest observed ǫ 1 is only around 0.01. On the other hand, allele frequency difference is large (0.03-0.07) due to the fact that these SNPs are selected by significant CAT0.5 test. A consequence of the two facts is that the angle with respect to the y-axis in Table 2 (B) tends to be small, with the exception of SNP rs27044 which is associated with ankylosing spondylitis
The closeness to the y axis of these SNPs on the phase diagram should indicate, on average, CAT0.5 test to be better than MAX2 test. Indeed, the X 2 (CAT0.5) test statistics are larger than X 2 (MAX2) except for two SNPs: rs27044 and rs2542151. It is not surprising to see rs27044 in the exception list as it has the largest angle with respect to the y-axis, and the negative sign of δ ǫ indicates that the disease model for rs27044 is more likely dominant. For rs27044, MAX2 test leads to a more significant result (p-value = 1.8 ×10 −7 ) than the CAT0.5 test (p-value= 10 −6 ). For rs2542151, its position in the phase diagram forms a smaller angle with the y-axis than the rs27044 SNP (8.5
• vs. 16.4
• ), but the angle is still large enough such that MAX2 leads to a more significant test (p-value =3.7 × 10 −14 ) than CAT0.5 test (p-value = 1.9 × 10 −13 ).
Discussion and conclusions
Our choice of δ p is to capture the linear or first-order term from the disease model or data, and δ ǫ to capture the nonlinear or second-order term. In quantitative genetics, there is a similar approach in using the additive variance σ 2 a and dominance variance σ 2 d (Fisher, 1918; Falconer and Mackay, 1996) . When these concepts from quantitative genetics are translated to dichotomous traits, σ
(see, e.g., Blackwelder and Elston, 1985) . Using Eq.
(1), we have
In other words, the square of our first-order parameter δ 2 p is proportional to the additive variance σ 2 a . Similarly, using Eq.(1) for δ ǫ , we have
When the disease prevalence K is low, δ ǫ is roughly proportional to f 2 f 0 − f 2 1 , as versus the
Actually, the HWD coefficient in the control group, which is small, is proportional to the difference between f 2 f 0 − f 2 1 and f 2 + f 0 − 2f 1 , and two are approximately equal when λ 1 , λ 2 are small (Zheng et al., 2006b) . Crudely, the square of δ ǫ can be said to be proportional to the dominance variance σ 2 d . The idea to use the test that is most powerful to the underlying model sounds straightforward, but in reality the true disease model is unknown. There have been attempts to infer the disease model by the HWD information. For example, (Wittke-Thompson et al., 2005) distinguishes HWD from different disease models and proposed its use for data fitting (note that the additive model defined in (Wittke-Thompson et al., 2005) , λ 2 = 2λ 1 , is different from that defined here, f 2 − f 1 = f 1 − f 0 or λ 2 = 2λ 1 − 1). In (Zheng and Ng, 2008) , the signs of ǫ 1 and ǫ 0 are used for genetic model selection: (+,−) for recessive models, (−,+) for dominant models, and (−,−) for multiplicative and additive models. Since the amount of HWD in control group is usually much smaller than that in case group, the sign of δ ǫ = ǫ 1 − ǫ 0 ≈ ǫ 1 may serve the purpose in selecting recessive and dominant models. All these previous works use HWD alone in genetic model selection, without considering a joint effect of HWD and allele frequency difference.
The result discussed in this paper shows that a joint consideration of δ ǫ and δ p could be more effective, than a consideration of δ ǫ only, in selecting disease model. The following simple procedure might be reasonable: first draw a line from origin to the data-determined (x, y) = (δ ǫ , δ p ) position, then calculate the angle formed by this line and the y-axis. If the angle is smaller than 3π/32 (or 16.875 • ), the underlying model is more likely to be multiplicative and CAT0.5 is the preferred test to use. On the other hand, if the angle with respect to the y-axis is larger, the underlying model is more likely to be recessive (if it's in the first quadrant) or dominant (second quadrant), and MAX2 is preferred over CAT0.5. A caution on this procedure is that, unless the sample size is very large and unless the true model is away from the phase transition line, the disease model can still be incorrectly inferred. The phase-diagram can also be used to summarize a case-control dataset with many SNPs. Using the phase diagram to examine the most recent whole-genome association data shows that SNPs with the strongest association signal tend to be multiplicative, and CAT0.5 test is more powerful than MAX2 test in this situation. However, we should not exclude the possibility that it is due to a selection bias, as the top ranking genes were chosen by CAT0.5 test result.
Also, if the most significant SNPs exhibit larger allele frequency differences, whereas their δ ǫ value is limited, their positions in the phase diagram is expected to be closer to the y-axis.
Whether the result in Table 2 (B) is due to selection bias or not, our approach could be useful in analyzing whole-genome association data, as illustrated by . The upper case is used when the power of MAX2 is larger than the power of CAT0.5, and lower case for the opposite. The model parameters are sampled from these ranges, population A-allele frequency is randomly sampled from (0-0.5), phenocopy rate f 0 from (10 −6 -10 −3 ), with the exception of over-dominant models, λ 2 from (1.001-2) and λ 1 is derived from λ 2 (λ 1 = λ 2 , 1, (λ 2 + 1)/2, √ λ 2 for for dominant, recessive, additive models, and multiplicative models). For over-dominant models, λ 1 is randomly chosen from (1.001-2), and λ 2 from (1.001, λ 1 ). as the y-axis, determined by comparing the empirical power of CAT0.5 and MAX2 tests. More than 10000 disease models are randomly sampled, each is used to randomly generate 5000 replicates of 500 cases and 500 controls. The empirical power of CAT0.5 and MAX2 based on these 5000 replicates are compared when the type I error is controlled at 0.05. A black circle is drawn when the empirical power of MAX2 is larger than that of CAT0.5, and a gray circle when CAT0.5 is more powerful than MAX2. If the empirical powers of both tests are larger than 0.99, a symbol "1" is marked. The two dashed lines form angles of 73.125
• and 106.875
• (13π/32 and 19π/32) with the x-axis, or, ±16.875
• (3π/32) with the y-axis. Note that rs3745064 is not on the y-axis, but inside the first quadrant, indicating that the recessive model describes its effect better than the multiplicative model.
